65,437 trials
Adult Acute Erythroid Leukemia (M6) · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Response Rate (RR) — 3 Participants
Diabetes Mellitus (DM)
Primary: Mean Daily Blood Glucose (BG) Concentration During Their Hospital Stay. — 221; 179; 222 mg/dL
Lung Cancer
Primary: Overall Survival and Progression Free Survival — 85.70; 60; 42.90; 28.10 percentage of participants (%)
Vasomotor Symptoms; Hot Flashes
Primary: Ratio of Week 4 to Baseline Average Number of Daily Moderate to Severe Hot Flashes — 0.35; 0.38 ratio — p=0.723
Fracture Mandible
Primary: Time to Place Archbars — 14.07; 37.29 minutes
Asthma
Primary: Change From Baseline in Asthma Control Test (ACT) Total Score at Week 12 — 2.8; 3.6 Scores on a Scale — p=0.033
Focus of Study is Teaching Crisis Resource Management
Primary: Total Ottawa GRS Score — 24.3; 21.8 units on a scale
Sexually Transmitted Infections
Primary: Number of Unprotected Acts of Intercourse — 19.7; 12.9; 18.2 # of unprotected sex acts at 12 months
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off — 64; 20 Participants
Perceptual Olfactory Bias
Primary: Percent Change in Olfactory Perceptual Bias — 21.33; -5 Percent of correctly identified odors — p=.08
Healthy
Primary: Peak Plasma Concentration (Cmax) of Montelukast — 415.6; 505.9 ng/mL
Sedentary Lifestyle · Self Efficacy · Control Locus
Primary: Steps — 6337.77; 6966.06; 6109.46; 8900.35 Daily Steps — p==.006
Sleep Apnea, Obstructive · Sleep Apnea Syndromes · Child Behavior Disorders
Primary: Change in Behavioral Index After 6 Months of CPAP or No-CPAP — -2.7; .9; -1.2 T score — p=0.07
Generalized Pustular Psoriasis (GPP) · Adalimumab · Japanese
Primary: Proportion of Participants Achieving Clinical Response at Week 16 — 7 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Mean GSK2269557 Plasma Concentration — 0.0; 0.0; 2175.5; 1871.8 Picograms per milliliter